APX-115 freebase
CAS No. 1270084-92-8
APX-115 freebase( Ewha 18278 | APX 115 | APX115 )
Catalog No. M11132 CAS No. 1270084-92-8
APX-115 (Ewha 18278)?is a first-in-class, orally active, pan-NADPH oxidase (Nox) inhibitor with Ki of 1.08, 0.57, 0.63 nM for Nox1, Nox2, and Nox4, respectively.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 110 | Get Quote |
|
| 10MG | 178 | Get Quote |
|
| 25MG | 357 | Get Quote |
|
| 50MG | 536 | Get Quote |
|
| 100MG | 779 | Get Quote |
|
| 200MG | Get Quote | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameAPX-115 freebase
-
NoteResearch use only, not for human use.
-
Brief DescriptionAPX-115 (Ewha 18278)?is a first-in-class, orally active, pan-NADPH oxidase (Nox) inhibitor with Ki of 1.08, 0.57, 0.63 nM for Nox1, Nox2, and Nox4, respectively.
-
DescriptionAPX-115 (Ewha 18278)?is a first-in-class, orally active, pan-NADPH oxidase (Nox) inhibitor with Ki of 1.08, 0.57, 0.63 nM for Nox1, Nox2, and Nox4, respectively; shows no inhibitory activities on xanthine oxidase and glucose oxidase; inhibits the responses of BMMs to RANKL, including ROS generation, activation of MAPK and NF-κB, and osteoclast cells differentiation; protects db/db mice from renal injury.Diabetes Preclinical.
-
In Vitro——
-
In VivoAnimal Model:Six-week-old male diabetic db/db mice (C57BLKS/J-leprdb/leprdb)Dosage:60?mg/kg Administration:Oral gavage; per day; for 12 weeks Result:Significantly improved insulin resistance in diabetic mice.
-
SynonymsEwha 18278 | APX 115 | APX115
-
PathwayMembrane Transporter/Ion Channel
-
TargetNADPH
-
RecptorNADPH
-
Research AreaMetabolic Disease
-
IndicationDiabetes
Chemical Information
-
CAS Number1270084-92-8
-
Formula Weight279.343
-
Molecular FormulaC17H17N3O
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 250 mg/mL (894.97 mM)
-
SMILES——
-
Chemical Name3-phenyl-1-(pyridin-2-yl)-4-propyl-1-5-hydroxypyrazol
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Cha JJ, et al. Lab Invest. 2017 Apr;97(4):419-431.
2. Kwon G, et al. Oncotarget. 2017 Jun 16. doi: 10.18632/oncotarget.18540.
3. Joo JH, et al. Sci Rep. 2016 Mar 15;6:22389.
molnova catalog
related products
-
Cozymasei(NAD+)
NAD+ is a coenzyme composed of ribosylnicotinamide 5'-diphosphate coupled to adenosine 5'-phosphate by pyrophosphate linkage.
-
GSK2795039
GSK2795039 inhibits reactive oxygen species (ROS) production and NADPH consumption. GSK2795039 decreases apoptosis. GSK2795039 is an inhibitor of NADPH oxidase 2 (NOX2) (pIC50: 6 in different cell-free assays). GSK2795039 (25 μM; 24 hours) decreases the combinatory effect of FeSO4 and LPS-increased levels of apoptosis.
-
APX-115
APX-115 (Ewha 18278)?is a first-in-class, orally active, pan-NADPH oxidase (Nox) inhibitor with Ki of 1.08, 0.57, 0.63 nM for Nox1, Nox2, and Nox4, respectively.
Cart
sales@molnova.com